Targeting EphB2 with rAAV-8-shEphB2 inhibited HCC tumor development and obviously sensitized HCC cells to sorafenib in an HCC immunocompetent mouse model (Leung et al., 2021). The gene discussed is EPHB2; the disease is neoplasm.